Abzena PLC Senior Executive Appointments
October 24 2016 - 1:00AM
RNS Non-Regulatory
TIDMABZA
Abzena PLC
24 October 2016
Abzena plc
Abzena makes two senior executive appointments to drive growth
of international business
Cambridge, UK, 24 October 2016 - Abzena plc (AIM: ABZA, 'Abzena'
or the 'Group'), a life sciences group providing services and
technologies to enable the development and manufacture of
biopharmaceutical products, announces that John Manzello and Sven
Lee have taken up senior executive appointments with Abzena in the
US as President, Abzena US and Chief Business Officer,
respectively.
John Manzello will be responsible for the Group's operations in
San Diego and Bristol, near Philadelphia, whilst Sven will lead
Abzena's global business development. These two appointments
provide strong industry experience to support and grow the
business, particularly in the US where Abzena is adding
manufacturing capacity and capability for antibodies and antibody
drug conjugates (ADCs).
John Manzello was previously President of San Diego's Promosome
LLC which he joined as President & CEO in April 2007. Using his
25 years of biotechnology executive and director level experience,
John expanded the business development, strategic alliances and
intellectual property portfolio for the company's suite of
synthetic biology technologies. Prior to joining Promosome, John's
relevant biotechnology experience included business and commercial
development roles at San Diego's Althea Technologies and
Massachusetts-based companies Cohesive Technologies, Genzyme
Transgenics (GTC) and GTC's contract subsidiary, Primedica.
Sven Lee joins Abzena from Terumo BCT where he was Director of
Global Sales & Business Development, focusing on cell therapy
technologies and licensing platform technologies to biotech
companies. He has 20 years of extensive business development, sales
and marketing expertise. Prior to Terumo BCT, Sven was Vice
President, Global Business Development for the biologics business
unit at Catalent Pharma Solutions, having previously held
commercial positions with Crucell (Johnson & Johnson), Biogen
and Sanofi.
Dr John Burt, Abzena's CEO, said:
"Bringing John and Sven on to the Abzena global executive
management team enables us to drive further growth of the US
business units and strengthens our international business
development activities. Recruitment of these highly experienced
individuals is a powerful endorsement of Abzena's ability to
deliver innovative and value-adding services and technology
solutions to enable the development of better
biopharmaceuticals."
Enquiries:
Abzena plc +44 1223 903498
John Burt, Chief Executive
Officer
Julian Smith, Chief Financial
Officer
Instinctif Partners +44 20 7457 2020
Melanie Toyne Sewell / abzena@instinctif.com
Rozi Morris
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and
complementary services to enable the development and manufacture of
biopharmaceutical products, a growing area that requires specialist
knowledge and expertise. The Group has a global customer base which
includes the majority of the top 20 biopharmaceutical companies as
well as large and small biotech companies and academic groups.
The term "Abzena inside" is used by Abzena to describe products
that have been created using its proprietary technologies and are
being developed by its partners, and include Composite Human
Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs).
Abzena has the potential to earn future licence fees, milestone
payments and/or royalties on "Abzena inside" products.
Abzena offers the following services and technologies across its
principal sites in Cambridge (UK), San Diego, California (USA) and
Bristol, Pennsylvania (USA).
-- Immunogenicity assessment, protein engineering to create
humanized antibodies and deimmunised therapeutic proteins, and cell
line development for manufacture.
-- Contract process development and manufacture of
biopharmaceuticals, including monoclonal antibodies, recombinant
proteins, vaccines, and gene therapy and cell therapy products, for
preclinical and clinical studies.
-- Proprietary site-specific conjugation technologies for
antibody drug conjugate development and solutions for optimizing
the therapeutic properties of biopharmaceuticals.
-- Contract chemistry and bioconjugation business focused on
ADCs and is establishing the capability to manufacture ADCs to GMP
standards.
For more information, please see www.abzena.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAKEFAEKKFFF
(END) Dow Jones Newswires
October 24, 2016 02:00 ET (06:00 GMT)
Abzena (LSE:ABZA)
Historical Stock Chart
From Apr 2024 to May 2024
Abzena (LSE:ABZA)
Historical Stock Chart
From May 2023 to May 2024